The U.S. Federal Trade Commission (FTC) announced last week that it is, for the second time, disputing hundreds of “junk” patents listed in the Food and Drug Administration’s (FDA) Orange Book, a list of FDA-approved drugs. The challenges span 20 different brand name drugs — including Novo Nordisk’s Ozempic — and is…
Originally published on Quartz : Original article